• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

作者信息

Jatiani Shashidhar S, Aleman Adolfo, Madduri Deepu, Chari Ajai, Cho Hearn Jay, Richard Shambavi, Richter Joshua, Brody Joshua, Jagannath Sundar, Parekh Samir

机构信息

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11.

DOI:10.1016/j.clml.2020.04.020
PMID:32553791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7484011/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f6/7484011/86ad47a38ac9/nihms-1603950-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f6/7484011/42b545fb118c/nihms-1603950-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f6/7484011/86ad47a38ac9/nihms-1603950-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f6/7484011/42b545fb118c/nihms-1603950-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2f6/7484011/86ad47a38ac9/nihms-1603950-f0002.jpg

相似文献

1
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.使用白细胞介素-1受体拮抗剂阿那白滞素治疗骨髓瘤嵌合抗原受体T细胞疗法相关的细胞因子释放综合征
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11.
2
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).单中心应用阿那白滞素治疗类固醇难治性免疫效应细胞相关性神经毒性综合征（ICANS）的经验。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003847.
3
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.双表位 CAR T 靶向 B 细胞成熟抗原治疗复发/难治性多发性骨髓瘤的探索性试验。
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551. doi: 10.1073/pnas.1819745116. Epub 2019 Apr 15.
4
Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.中性粒细胞激活和克隆 CAR-T 再扩增是多发性骨髓瘤患者 cilta-cabtagene autoleucel 治疗中细胞因子释放综合征的基础。
Nat Commun. 2024 Jan 8;15(1):360. doi: 10.1038/s41467-023-44648-3.
5
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
6
Management of cytokine release syndrome related to CAR-T cell therapy.细胞因子释放综合征相关的 CAR-T 细胞治疗的管理。
Front Med. 2019 Oct;13(5):610-617. doi: 10.1007/s11684-019-0714-8. Epub 2019 Sep 28.
7
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.
8
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.多发性骨髓瘤中双特异性抗体和嵌合抗原受体 T 细胞治疗相关不良事件的预防和管理：欧洲骨髓瘤网络共识报告。
Lancet Oncol. 2023 Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6.
9
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).嵌合抗原受体 T 细胞（CAR-T）治疗的成年人中的心血管事件。
J Am Coll Cardiol. 2019 Dec 24;74(25):3099-3108. doi: 10.1016/j.jacc.2019.10.038.
10
[Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].[CAR-T治疗后多发性骨髓瘤患者细胞因子释放综合征相关早期预警指标分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1203-1208. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.028.

引用本文的文献

1
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.欧洲血液学年会-欧洲骨髓瘤网络关于多发性骨髓瘤患者诊断、治疗及随访的循证指南
Nat Rev Clin Oncol. 2025 Jul 7. doi: 10.1038/s41571-025-01041-x.
2
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma.多发性骨髓瘤双特异性T细胞衔接器疗法的门诊给药前景
Curr Oncol. 2025 Apr 18;32(4):238. doi: 10.3390/curroncol32040238.
3
A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator.

本文引用的文献

1
CAR T Cell Toxicity: Current Management and Future Directions.嵌合抗原受体T细胞毒性：当前管理与未来方向
Hemasphere. 2019 Mar 29;3(2):e186. doi: 10.1097/HS9.0000000000000186. eCollection 2019 Apr.
2
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
3
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
白细胞介素-1在嵌合抗原受体T细胞疗法中的双重作用：增强剂与缓解剂的系统评价
Iran Biomed J. 2024 Sep 1;28(5 & 6):221-34. doi: 10.61186/ibj.4444.
4
Targeting cytokine networks in neuroinflammatory diseases.靶向神经炎症性疾病中的细胞因子网络。
Nat Rev Drug Discov. 2024 Nov;23(11):862-879. doi: 10.1038/s41573-024-01026-y. Epub 2024 Sep 11.
5
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.多发性骨髓瘤中针对 BCMA、GPRC5D 和 FcRH5 的双特异性抗体相关毒性的管理。
Curr Hematol Malig Rep. 2024 Dec;19(6):237-245. doi: 10.1007/s11899-024-00740-z. Epub 2024 Aug 15.
6
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.减瘤治疗对阿基仑赛治疗复发或难治性大B细胞淋巴瘤临床结局的影响。
Am J Cancer Res. 2024 Jun 15;14(6):2905-2920. doi: 10.62347/LLXR8002. eCollection 2024.
7
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
8
Current understanding and management of CAR T cell-associated toxicities.嵌合抗原受体 T 细胞相关毒性的现有认识和管理。
Nat Rev Clin Oncol. 2024 Jul;21(7):501-521. doi: 10.1038/s41571-024-00903-0. Epub 2024 May 20.
9
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.继发性噬血细胞性淋巴组织细胞增多症/巨噬细胞活化综合征的免疫病理学及潜在治疗策略：转化医学视角
Exp Mol Med. 2024 Mar;56(3):559-569. doi: 10.1038/s12276-024-01182-6. Epub 2024 Mar 6.
10
Managing side effects: guidance for use of immunotherapies in multiple myeloma.管理副作用：免疫疗法在多发性骨髓瘤中的应用指南。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):348-356. doi: 10.1182/hematology.2023000435.
嵌合抗原受体 T 细胞引起的细胞因子释放综合征是由巨噬细胞介导的，并可通过白细胞介素-1 阻断来减轻。
Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28.
4
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
5
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
6
FDA Approves Second CAR T-cell Therapy.美国食品药品监督管理局批准第二种嵌合抗原受体T细胞疗法。
Cancer Discov. 2018 Jan;8(1):5-6. doi: 10.1158/2159-8290.CD-NB2017-155. Epub 2017 Nov 7.
7
First-Ever CAR T-cell Therapy Approved in U.S.首款 CAR T 细胞疗法获美国批准
Cancer Discov. 2017 Oct;7(10):OF1. doi: 10.1158/2159-8290.CD-NB2017-126. Epub 2017 Sep 8.
8
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.依鲁替尼治疗失败后，用CD19特异性嵌合抗原受体修饰的T细胞治疗慢性淋巴细胞白血病的持久分子缓解。
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
9
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.托珠单抗对成年类风湿关节炎患者中性粒细胞的影响：3期和4期临床试验数据的汇总分析
Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370.
10
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病后的细胞因子释放综合征
Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.